Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer.
Green HongPureum SunChaeuk ChungDong Il ParkSong I LeeNayoung KimSeong Eun LeeJeong Eun LeeYea Eun KangDa Hyun KangPublished in: Journal of cancer research and clinical oncology (2022)
Plasma GDF15 could be a potential biomarker for predicting the efficacy and survival benefit of immunotherapy in advanced NSCLC.